GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX 1,377.50
+13.50 (0.99%)
May 9, 2025, 4:35 PM BST
GSK plc Revenue
GSK plc had revenue of 7.52B GBP in the quarter ending March 31, 2025, with 2.08% growth. This brings the company's revenue in the last twelve months to 31.53B, up 2.57% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.53B
Revenue Growth
+2.57%
P/S Ratio
1.76
Revenue / Employee
459.41K
Employees
68,629
Market Cap
55.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
| Oxford Nanopore Technologies | 183.19M |
GSK plc News
- 5 hours ago - GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis - Business Wire
- 1 day ago - GSK met main goal in liver disease treatment trial - Seeking Alpha
- 1 day ago - EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug - Reuters
- 3 days ago - Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aide - report - Seeking Alpha
- 4 days ago - 5 Reasons GSK Looks Good - Seeking Alpha
- 4 days ago - GSK declares $0.4216 dividend - Seeking Alpha
- 8 days ago - Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Benzinga
- 8 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC